AU2020347578A1 - Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness - Google Patents
Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness Download PDFInfo
- Publication number
- AU2020347578A1 AU2020347578A1 AU2020347578A AU2020347578A AU2020347578A1 AU 2020347578 A1 AU2020347578 A1 AU 2020347578A1 AU 2020347578 A AU2020347578 A AU 2020347578A AU 2020347578 A AU2020347578 A AU 2020347578A AU 2020347578 A1 AU2020347578 A1 AU 2020347578A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- effective amount
- methyl
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900310P | 2019-09-13 | 2019-09-13 | |
| US62/900,310 | 2019-09-13 | ||
| US202063031687P | 2020-05-29 | 2020-05-29 | |
| US63/031,687 | 2020-05-29 | ||
| PCT/IB2020/058482 WO2021048821A1 (en) | 2019-09-13 | 2020-09-12 | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020347578A1 true AU2020347578A1 (en) | 2022-04-14 |
Family
ID=72521681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020347578A Abandoned AU2020347578A1 (en) | 2019-09-13 | 2020-09-12 | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220331303A1 (https=) |
| EP (1) | EP4028003A1 (https=) |
| JP (1) | JP2022547604A (https=) |
| KR (1) | KR20220062361A (https=) |
| CN (1) | CN114555083A (https=) |
| AU (1) | AU2020347578A1 (https=) |
| BR (1) | BR112022004576A2 (https=) |
| CA (1) | CA3154320A1 (https=) |
| CO (1) | CO2022004589A2 (https=) |
| MX (1) | MX2022003017A (https=) |
| WO (1) | WO2021048821A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065585B1 (en) | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| AU2021205892B2 (en) | 2020-01-10 | 2026-04-23 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 |
| CN116583502A (zh) | 2020-09-03 | 2023-08-11 | 欧瑞夏治疗有限公司 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2024075825A1 (ja) | 2022-10-07 | 2024-04-11 | キッセイ薬品工業株式会社 | シクロペンタン化合物 |
| EP4719397A1 (en) * | 2023-06-02 | 2026-04-08 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for improving respiratory function during sleep |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| PT929574E (pt) | 1996-08-27 | 2005-11-30 | Praecis Pharm Inc | Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos |
| EP1196609A2 (en) | 1999-06-28 | 2002-04-17 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
| LT3984994T (lt) * | 2016-02-04 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti |
| JOP20190008A1 (ar) * | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| AU2020346456A1 (en) * | 2019-09-13 | 2022-04-14 | Takeda Pharmaceutical Company Limited | TAK-925 for use in treating narcolepsy |
-
2020
- 2020-09-12 KR KR1020227011859A patent/KR20220062361A/ko active Pending
- 2020-09-12 BR BR112022004576A patent/BR112022004576A2/pt unknown
- 2020-09-12 CA CA3154320A patent/CA3154320A1/en active Pending
- 2020-09-12 AU AU2020347578A patent/AU2020347578A1/en not_active Abandoned
- 2020-09-12 CN CN202080072019.0A patent/CN114555083A/zh active Pending
- 2020-09-12 EP EP20772441.0A patent/EP4028003A1/en not_active Withdrawn
- 2020-09-12 WO PCT/IB2020/058482 patent/WO2021048821A1/en not_active Ceased
- 2020-09-12 JP JP2022516271A patent/JP2022547604A/ja active Pending
- 2020-09-12 US US17/642,337 patent/US20220331303A1/en not_active Abandoned
- 2020-09-12 MX MX2022003017A patent/MX2022003017A/es unknown
-
2022
- 2022-04-11 CO CONC2022/0004589A patent/CO2022004589A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220331303A1 (en) | 2022-10-20 |
| KR20220062361A (ko) | 2022-05-16 |
| MX2022003017A (es) | 2022-06-14 |
| CA3154320A1 (en) | 2021-03-18 |
| JP2022547604A (ja) | 2022-11-14 |
| EP4028003A1 (en) | 2022-07-20 |
| CO2022004589A2 (es) | 2022-04-29 |
| WO2021048821A1 (en) | 2021-03-18 |
| CN114555083A (zh) | 2022-05-27 |
| WO2021048821A8 (en) | 2021-11-04 |
| BR112022004576A2 (pt) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331303A1 (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness | |
| US20220339143A1 (en) | Tak-925 for use in treating narcolepsy | |
| US11123313B2 (en) | Methods and compositions for treating sleep apnea | |
| US9700548B2 (en) | Antihistamines combined with dietary supplements for improved health | |
| US12594269B2 (en) | Method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 | |
| JP2025510294A (ja) | 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン | |
| Thase et al. | Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review | |
| WO2022190060A1 (en) | An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder | |
| CN111135304A (zh) | 治疗慢性、顽固性或原发性失眠症的联合用药物及其应用 | |
| AU2022252108A1 (en) | Use of an orexin 2 receptor agonist for post operation recovery | |
| KR20170005415A (ko) | 과수면증의 치료 방법 | |
| US20240284941A1 (en) | Antihistamines combined with dietary supplements for improved health | |
| RU2834228C1 (ru) | Способ улучшения фармокинетики или повышения концентрации в плазме метил-3-((метилсульфонил)амино)-2-(((4-фенилциклогексил)окси)метил)пиперидин-1-карбоксилата или его соли с помощью ингибитора цитохрома p450 | |
| Murata et al. | Recovery Time Following Continuous Midazolam Infusion During Dental Implant Surgery: A Prospective Observational Study | |
| WO2025240537A1 (en) | Methods of treating psychiatric disorders or pain using (r)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-one or pharmaceutically acceptable salts thereof | |
| Vimmerová-Lattová | Endocrine and Metabolic Aspects of Various Sleep Disorders | |
| EP2269600A1 (en) | Treatment of sleep disorders using eplivanserin in COPD patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |